How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Anthropic recursive self improvement, Brian Patrick Green tech ethics, AI regulation slowdown, Pope Leo XIV AI encyclical, ...

Spread the love“`html The landscape of artificial intelligence is constantly evolving, and the idea of Recursive Self-Improvement (RSI) is gaining traction as a potential game-changer. With ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Buy: Anthropic exposure via its likely IPO/secondary path (e.g., IPO allocation or liquid proxy like AI-safety/compute beneficiaries). Rationale: Anthropic is pushing “slow/pause” policy while still ...

Anthropic warns self‑improving AI could outpace human control, urging a slowdown as risks grow and systems begin advancing on their own.

Anthropic's AI, Claude, now writes 80% of the company's code, sparking discussions on AI's potential to replace traditional engineering roles and its impact on work culture.

Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he insists it will actually ship products.

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Apart from being a box office smash hit, "Project Hail Mary" represents the kind of optimistic science fiction storytelling we need at the moment. The Ryan Gosling vehicle does justice to Andy Weir's ...